Agenus Inc. Overview
Pro stress-test →Agenus is a clinical-stage biotechnology company that discovers and develops therapies to activate the body's immune system against cancer and infections. The company operates a comprehensive immuno-oncology pipeline with collaborations with Bristol-Myers Squibb, Gilead Sciences, Incyte Corporation, and Merck Sharp & Dohme.
Strategic Profile
Pro stress-test →The company is focused on expanding patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. In 2025, Agenus sold their CDMO business to Zydus Lifesciences and partnered with Zydus to commercialize their molecules in India.
Competitive Landscape
Pro stress-test →Agenus competes in immuno-oncology with major players including Bristol-Myers Squibb, Merck, Incyte, and Gilead across checkpoint inhibitors and adoptive cell therapies. The company differentiates through its Retrocyte Display antibody platform, QS-21 Stimulon adjuvant, and Prophage personalized cancer vaccines. Partnerships amplify reach rather than direct competition.
Industry Context
Agenus Inc. operates in Biotechnology - Immuno-Oncology.
Key facts
Founded: 1994 · Headquarters: Lexington, Massachusetts · Employees: N/A · Revenue: N/A · Market cap: N/A